The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...

Exelixis has won U.S. Food and Drug Administration expanded approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

The tumors begin in neuroendocrine cells – which have characteristics ... most often in the gastrointestinal tract, lungs, and pancreas. The number of people diagnosed with NETs has been ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Hampshire-based PLANETS Cancer Charity welcomed the decision by the National Institute for Health and Care Excellence (NICE) ...